Comparative *in vitro* Activities of Torezolid (TR-700, DA-7157) against Clinical Isolates of Aerobic and Anaerobic Bacteria in Korea

Antimicrobial Agents and Chemotherapy. 2010 Sep; Published Online Ahead of Print

Yum J, Choi S, Yong D, Chong Y, IM W, Rhee D, Lee K

Department of Clinical Laboratory Science, Dong-eui University, Busan, Korea; Research Laboratory, Dong-A Pharmaceutical Co., Ltd., Yongin, Korea; and College of Pharmacy, Sungkyunkwan University, Suwon, Korea; Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul, Korea

Resistance of Gram-positive pathogens to first-line antimicrobial agents has been increasing in many parts of world. We compared the *in vitro* activities of torezolid with those of other antimicrobial agents including linezolid against clinical isolates of major aerobic and anaerobic bacteria. Torezolid had an MIC_{90} of 0.5 μg/ml for the Gram-positive bacterial isolates and was more potent than either linezolid or vancomycin.